$OTLC
Oncotelic Therapeutics, Inc.

2014 Q2 Form 10-Q Financial Statement

#000119312514189844 Filed on May 08, 2014

View on sec.gov

Income Statement

Concept 2014 Q2 2014 Q1 2013 Q1
Revenue $0.00 $0.00 $0.00
YoY Change -100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.750M $1.240M $1.140M
YoY Change 66.67% 8.77% -14.29%
% of Gross Profit
Research & Development $2.171M $1.387M $746.0K
YoY Change 260.03% 85.92% 14.77%
% of Gross Profit
Depreciation & Amortization $40.00K $4.000K $3.000K
YoY Change 0.0% 33.33% -92.5%
% of Gross Profit
Operating Expenses $3.924M $2.628M $1.881M
YoY Change 137.1% 39.71% -5.48%
Operating Profit -$3.924M -$2.628M -$1.881M
YoY Change 137.1% 39.71%
Interest Expense $0.00 $0.00 $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net -$6.000K -$3.000K $0.00
YoY Change -100.0%
Pretax Income -$3.930M -$2.630M -$1.880M
YoY Change 138.18% 39.89% -0.53%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$3.929M -$2.630M -$1.880M
YoY Change 137.55% 39.89% -0.53%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$0.23 -$0.29 -$0.97
COMMON SHARES
Basic Shares Outstanding 15.30M shares 15.24M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q2 2014 Q1 2013 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $36.27M $24.74M $4.560M
YoY Change 369.21% 442.54% -44.05%
Cash & Equivalents $36.27M $24.74M $4.560M
Short-Term Investments
Other Short-Term Assets $18.00K $41.00K $450.0K
YoY Change -95.71% -90.89% -4.26%
Inventory
Prepaid Expenses $450.0K $368.0K
Receivables
Other Receivables
Total Short-Term Assets $36.74M $25.14M $5.010M
YoY Change 350.23% 401.88% -41.81%
LONG-TERM ASSETS
Property, Plant & Equipment $28.00K $32.00K $10.00K
YoY Change 180.0% 220.0% -66.67%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $33.00K
YoY Change
Total Long-Term Assets $108.0K $102.0K $170.0K
YoY Change -28.0% -40.0% -55.26%
TOTAL ASSETS
Total Short-Term Assets $36.74M $25.14M $5.010M
Total Long-Term Assets $108.0K $102.0K $170.0K
Total Assets $36.85M $25.25M $5.180M
YoY Change 343.41% 387.37% -42.38%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $849.0K $432.0K $450.0K
YoY Change 97.44% -4.0% 221.43%
Accrued Expenses $1.100M $960.0K $390.0K
YoY Change 139.13% 146.15% -70.68%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.948M $1.395M $830.0K
YoY Change 118.88% 68.07% -43.54%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change -100.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.948M $1.395M $830.0K
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.950M $1.400M $830.0K
YoY Change 119.1% 68.67% -43.92%
SHAREHOLDERS EQUITY
Retained Earnings -$245.1M -$241.1M
YoY Change
Common Stock $280.0M $265.0M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $34.90M $23.85M $4.350M
YoY Change
Total Liabilities & Shareholders Equity $36.85M $25.25M $5.180M
YoY Change 343.41% 387.37% -42.38%

Cashflow Statement

Concept 2014 Q2 2014 Q1 2013 Q1
OPERATING ACTIVITIES
Net Income -$3.929M -$2.630M -$1.880M
YoY Change 137.55% 39.89% -0.53%
Depreciation, Depletion And Amortization $40.00K $4.000K $3.000K
YoY Change 0.0% 33.33% -92.5%
Cash From Operating Activities -$3.310M -$2.624M -$1.894M
YoY Change 128.28% 38.54% -32.11%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $10.86M $1.510M
YoY Change 619.21% 57.29%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.84M 20.35M 1.510M
YoY Change 221.21% 1247.95% 57.29%
NET CHANGE
Cash From Operating Activities -3.310M -2.624M -1.894M
Cash From Investing Activities
Cash From Financing Activities 14.84M 20.35M 1.510M
Net Change In Cash 11.53M 17.73M -384.0K
YoY Change 263.72% -4717.19% -79.02%
FREE CASH FLOW
Cash From Operating Activities -$3.310M -$2.624M -$1.894M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2926829 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right
ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight
0.5 shares
CY2014Q1 us-gaap Share Price
SharePrice
2.05
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.75
CY2014Q1 oxgn Threshold Limit Percentage On Warrants Owned
ThresholdLimitPercentageOnWarrantsOwned
0.0999 pure
CY2014Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
15300820 shares
CY2013Q2 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
1377412 shares
CY2013Q1 us-gaap Cash
Cash
4562000
CY2014Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15294000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
143000 shares
CY2014Q1 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
1048125 shares
CY2014Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15294000 shares
CY2014Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
10.33
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
248000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
10.86
CY2014Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
4548000 shares
CY2014Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
222000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
13.59
CY2014Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2014Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2014Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2014Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
2.24
CY2014Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1091000
CY2014Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
432000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
133000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
221000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
6043000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
458000
CY2014Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1395000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
112000
CY2014Q1 us-gaap Stockholders Equity
StockholdersEquity
23851000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
208000
CY2014Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
272000
CY2014Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
448000
CY2014Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
264836000
CY2014Q1 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2014Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-241138000
CY2014Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1430000
CY2014Q1 us-gaap Common Stock Value
CommonStockValue
153000
CY2014Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
25246000
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
215000
CY2014Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2014Q1 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
202000
CY2014Q1 us-gaap Assets Current
AssetsCurrent
25144000
CY2014Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
368000
CY2014Q1 us-gaap Assets
Assets
25246000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
78000
CY2014Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
70000
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
51000
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
86000
CY2014Q1 us-gaap Other Assets Current
OtherAssetsCurrent
41000
CY2014Q1 us-gaap Cash
Cash
24735000
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
202795
CY2014Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
32000
CY2014Q1 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
515000
CY2014Q1 oxgn Purchase Commitment Amount Due
PurchaseCommitmentAmountDue
1617000
CY2014Q1 oxgn Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights Related Party
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRightsRelatedParty
147145 shares
CY2014Q1 oxgn Future Purchase Commitment
FuturePurchaseCommitment
1089000
CY2014Q1 oxgn Purchase Commitment Estimated And Accrued
PurchaseCommitmentEstimatedAndAccrued
444000
CY2014Q1 oxgn Purchase Commitment Non Cancelable Contracts Obligation
PurchaseCommitmentNonCancelableContractsObligation
191000
CY2012Q4 us-gaap Cash
Cash
4946000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5586000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5586000 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.54
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
192000 shares
CY2013Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
5178000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
15000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
70000000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
268000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
476000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1251000
CY2013Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
244495000
CY2013Q4 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
0
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-238508000
CY2013Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
1406000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
56000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7294000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Assets Current
AssetsCurrent
7165000
CY2013Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
93000
CY2013Q4 us-gaap Assets
Assets
7294000
CY2013Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
93000
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
67000
CY2013Q4 us-gaap Cash
Cash
7005000
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
36000
CY2013Q4 oxgn Accrued Research And Development
AccruedResearchAndDevelopment
317000
CY2014Q1 us-gaap Stock Issued During Period Shares New Issues
StockIssuedDuringPeriodSharesNewIssues
5853657 shares
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
10860000
CY2014Q1 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2014Q1 oxgn Proceeds From Issuance Of Common Stock And Warrants In Offering Gross
ProceedsFromIssuanceOfCommonStockAndWarrantsInOfferingGross
12000000
CY2013Q2 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5000000
CY2013Q2 oxgn Net Proceeds From Issuance Initial Public Offering
NetProceedsFromIssuanceInitialPublicOffering
4192000
CY2013Q3 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
5800000
CY2013Q3 oxgn Proceeds From Issuance Initial Public Offering Net
ProceedsFromIssuanceInitialPublicOfferingNet
4905000
CY2011 us-gaap Cost Of Goods Sold
CostOfGoodsSold
0
CY2013Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
1940000 shares
CY2013Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1894000
CY2013Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.97
CY2013Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
146000
CY2013Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2013Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1881000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-1880000
CY2013Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-68000
CY2013Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1135000
CY2013Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1510000
CY2013Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
24000
CY2013Q1 us-gaap Share Based Compensation
ShareBasedCompensation
173000
CY2013Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-384000
CY2013Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1510000
CY2013Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
746000
CY2013Q1 us-gaap Depreciation
Depreciation
3000
CY2013Q1 us-gaap Operating Expenses
OperatingExpenses
1881000
CY2014Q1 dei Entity Registrant Name
EntityRegistrantName
OXIGENE INC
CY2014Q1 dei Amendment Flag
AmendmentFlag
false
CY2014Q1 dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
CY2014Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q1 dei Document Type
DocumentType
10-Q
CY2014Q1 dei Document Period End Date
DocumentPeriodEndDate
2014-03-31
CY2014Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000908259
CY2014Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2014Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P7Y4M17D
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0170 pure
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.97 pure
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y7M10D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P4Y
CY2014Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
9054000 shares
CY2014Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.74
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.0000 pure
CY2014Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2624000
CY2014Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.29
CY2014Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
56000 shares
CY2014Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P2Y7M6D
CY2014Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M4D
CY2014Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 6pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with U.S.&#xA0;generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of income and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2014Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
249000
CY2014Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2014Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
CY2014Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2628000
CY2014Q1 us-gaap Long Term Purchase Commitment Amount
LongTermPurchaseCommitmentAmount
1173000
CY2014Q1 us-gaap Net Income Loss
NetIncomeLoss
-2630000
CY2014Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
144000
CY2014Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1241000
CY2014Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
20354000
CY2014Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
9494000
CY2014Q1 us-gaap Adjustment For Amortization
AdjustmentForAmortization
23000
CY2014Q1 us-gaap Share Based Compensation
ShareBasedCompensation
84000
CY2014Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
17730000
CY2014Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
10860000
CY2014Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1387000
CY2014Q1 us-gaap Depreciation
Depreciation
4000
CY2014Q1 us-gaap Operating Expenses
OperatingExpenses
2628000
CY2014Q1 oxgn Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Remaining Contractual Term Two
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermTwo
P7Y6M18D
CY2014Q1 oxgn Class Of Warrant Or Right Number Of Warrants Exercised
ClassOfWarrantOrRightNumberOfWarrantsExercised
1048125 shares
CY2014Q1 oxgn Class Of Warrant Or Right Term
ClassOfWarrantOrRightTerm
P5Y
CY2014Q1 oxgn Number Of Drug Candidates
NumberOfDrugCandidates
2 Candidate
CY2014Q1 oxgn Classes Of Warrants Or Right Term Exercise Period
ClassesOfWarrantsOrRightTermExercisePeriod
P5Y
CY2014Q1 oxgn Classes Or Warrant Right Expiration Date
ClassesOrWarrantRightExpirationDate
2014-07-20
CY2014Q1 oxgn Inspection Period For Product Defects
InspectionPeriodForProductDefects
P30D
CY2014Q1 oxgn Percentage Of Distribution Revenue On Gross Margin Earned
PercentageOfDistributionRevenueOnGrossMarginEarned
0.20 pure

Files In Submission

Name View Source Status
0001193125-14-189844-index-headers.html Edgar Link pending
0001193125-14-189844-index.html Edgar Link pending
0001193125-14-189844.txt Edgar Link pending
0001193125-14-189844-xbrl.zip Edgar Link pending
d714435d10q.htm Edgar Link pending
d714435dex101.htm Edgar Link pending
d714435dex311.htm Edgar Link pending
d714435dex312.htm Edgar Link pending
d714435dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g714435g11a90.jpg Edgar Link pending
oxgn-20140331.xml Edgar Link completed
oxgn-20140331.xsd Edgar Link pending
oxgn-20140331_cal.xml Edgar Link unprocessable
oxgn-20140331_def.xml Edgar Link unprocessable
oxgn-20140331_lab.xml Edgar Link unprocessable
oxgn-20140331_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending